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Objective: Treatment options for patients with advanced pulmonary vascular
disease caused by a congenital heart defect are still mainly limited to heart-
lung transplantation or lung transplantation with repair of the cardiac lesion.
Because we have previously shown that the structural changes associated
with pulmonary hypertension can be reversed by stress unloading in an organ
culture model, we now investigate whether hemodynamic unloading will
lead to regression of pulmonary vascular disease in the intact animal. 
Methods: Right middle and lower lobectomy and monocrotaline injection
were performed in Lewis rats (n = 22) to cause pulmonary vascular disease
from a combined hemodynamic and toxic injury. Twenty-eight days later the
left lungs were examined (n = 10) or exposed to normal pulmonary artery
pressure for an additional 14 (n = 5) or 28 (n = 7) days by transplantation
into healthy recipients. Pulmonary artery pressure, ventricular weight, and
pulmonary artery morphology were evaluated in each group. 
Results: Pulmonary hypertension (50 vs 16 mm Hg; P < .001) and right ven-
tricular hypertrophy (right ventricular/left ventricular weight 0.69 vs 0.32; 
P < .001) associated with pulmonary artery medial hypertrophy (28.2% vs
7.2% wall thickness; P < .001) and muscularization of small pulmonary
arteries (92.3% vs 19.4%; P < .001) developed by day 28 (compared with
untreated controls). However, transplantation into healthy recipients effec-
tively unloaded the lungs (mean pulmonary artery pressure 17 and 24 mm
Hg at 14 and 28 days after transplantation) and resulted in progressive nor-
malization of medial hypertrophy (15.6% and 12.1% at 14 and 28 days) and
muscularization (65.1% and 42.2% at 14 and 28 days) relative to nontrans-
planted controls (P < .005 in each case). 
Conclusions: Hemodynamic unloading of lungs with pulmonary vascular dis-
ease results in progressive normalization of pulmonary artery structure.
These results are the first to provide a rationale for attempting to induce
regression of pulmonary vascular disease by pressure unloading of the pul-
monary circulation. Methods to mechanically unload the pulmonary circula-
tion should be critically evaluated as a strategy for staged surgical repair of
congenital heart defects despite presumed irreversible pulmonary hyperten-
sion. (J Thorac Cardiovasc Surg 2001;121:279-89)
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O bstructive pulmonary vascular disease caused by achronic left-to-right shunt complicates certain con-
genital heart defects if not repaired early in life.
Elevated and fixed pulmonary vascular resistance pre-
disposes the patient to postoperative pulmonary hyper-
tension and right ventricular (RV) failure and may
make the risk of surgical correction prohibitive. The
treatment options for patients with advanced pul-
monary vascular disease associated with a congenital
heart defect are currently limited to heart-lung trans-
plantation or lung transplantation and simultaneous
intracardiac repair.1-4 Long-term intravenous epopro-
stenol (formerly, prostacyclin) infusion may reduce
pulmonary vascular resistance and improve the hemo-
dynamics in this group of patients.5 However, a method
of reversing the structural changes in the pulmonary
circulation may allow surgical repair of the congenital
heart defect with an acceptable risk.
Obstructive pulmonary vascular disease in patients
with a congenital heart defect is characterized by thick-
ening of the medial layer of larger muscular arteries as
a result of smooth muscle cell proliferation and hyper-
trophy. Furthermore, the medial smooth muscle layer
extends to the smaller, normally nonmuscular peripher-
al pulmonary arteries (PAs). These features, along with
neointimal proliferation and obliteration of peripheral
PAs associated with reduced arterial density, all con-
tribute to the increase in pulmonary vascular resis-
tance.6-9 We have previously demonstrated, in an organ
culture model, that unloading mechanical stress revers-
es the structural changes associated with pulmonary
hypertension by triggering smooth muscle cell apopto-
sis and extracellular matrix resorption.10 Improvement
in the biopsy findings in patients with pulmonary vas-
cular disease after banding of the PA has been reported
in a few patients11 and could similarly be due to an
unloading of hemodynamic forces. 
To test the hypothesis that hemodynamic unloading
leads to regression of the structural changes associated
with obstructive pulmonary vascular disease, we adapt-
ed an animal model of pulmonary hypertension.
Increased pulmonary blood flow induced by pulmonary
resection and endothelial injury caused by the toxin
monocrotaline in the rat result in PA changes that share
many features with the human disease.12,13 To model
hemodynamic unloading in vivo, we transplanted lungs
from rats with pulmonary hypertension into normoten-
sive recipient rats and examined them 14 and 28 days
later to evaluate regression of the structural changes.
Our data indicate that hemodynamic unloading of lungs
with pulmonary vascular disease leads to a progressive
normalization of the structural changes associated with
pulmonary vascular disease including medial hypertro-
phy and muscularization of peripheral PAs. Regression
of the pulmonary vascular changes is associated with a
reduction in cellular proliferation rates. These data sup-
port the hypothesis that obstructive pulmonary vascular
disease can be reversed by hemodynamic unloading. If
a method of safely unloading the pulmonary circulation
can be devised, it may allow for staged repair of con-
genital heart defects with acceptable risk despite pre-
sumed irreversible pulmonary vascular disease. 
Methods
Experimental design. Forty-one syngeneic adult Lewis
rats (Charles River Laboratories, St Laurent, Quebec,
Canada) with an average body weight of 358 ± 8 g were ran-
domly selected as untreated controls (n = 4) or subjected to
right middle and lower lobectomy followed by injection of
monocrotaline (n = 37) to induce pulmonary hypertension.
Twenty-eight days after right lung resection and monocro-
taline injection, left lungs from the surviving rats (n = 30)
were harvested for morphometric evaluation (n = 10) or
exposed to normal PA pressures by orthotopic transplantation
into healthy normotensive recipients (n = 20). Because
monocrotaline-induced pulmonary vascular disease is pro-
gressive and fatal beyond 28 days,14 the remaining lungs (n =
10) were also harvested on day 28 and served as a control
group. The transplanted left lungs were then recovered from
the surviving recipients 14 (n = 5) or 28 (n = 7) days after
transplantation. PA pressure, RV hypertrophy, PA morpholo-
gy, and cellular proliferation were evaluated in each group.
All animals received standard postoperative care according to
protocols approved by the Animal Care Committee of the
Hospital for Sick Children and in compliance with guidelines
from the Canadian National Society for Medical Research. 
Anesthesia and postoperative care. Rats were sedated by
an intraperitoneal injection of ketamine (7 mg/kg; Parke-
Davis, Toronto, Ontario, Canada), anesthetized with isoflu-
rane (Zeneca, Mississauga, Ontario, Canada) and nitrous
oxide, and then intubated endotracheally with a 14-gauge
intravenous catheter. The animals’ lungs were ventilated with
a volume-controlled ventilator (Harvard rodent ventilator,
model 683; Harvard Apparatus Company, S Natick, Mass) at
a rate of 80 breaths/min and a tidal volume of 1 mL/100 g
with a positive end-expiratory pressure of 2 cm H2O. The
electrocardiogram was continuously monitored. An 18-gauge
intravenous catheter attached to an underwater seal and suc-
tion was used to evacuate the pleural space on closure of the
thoracotomy incision. At the termination of the surgical pro-
cedure, the animals were ventilated with 100% oxygen and
allowed to awaken. When spontaneous breathing was
observed, the animals were extubated and the pleural catheter
removed. Buprenorphine (0.05 mg/kg; Reckitt & Coleman
Pharmaceutical Inc, Richmond, Va) was administered for
pain control by intraperitoneal injection immediately after
extubation and as required during the postoperative period. 
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Right lung resection and monocrotaline injection. After
the administration of anesthesia, endotracheal intubation, and
ventilation, a right thoracotomy was performed in the fifth
intercostal space. The right middle and lower lobe vein,
artery, and bronchus were ligated with a silk suture, and the
middle and lower lobes of the lung were removed. A chest
tube was left in the pleural space and the thoracotomy wound
was closed in layers with absorbable sutures. The alkaloid
toxin monocrotaline (Sigma Chemical Co, St Louis, Mo) was
dissolved in HCl (1 mol/L), diluted with sterile water (40
mg/mL), adjusted to pH 7.0, and filtered (0.2 µm pore size).
Monocrotaline (60 mg/kg) was injected subcutaneously once
the rats were extubated.
Left lung harvest and transplantation. Left lungs were
harvested from pulmonary hypertensive rats 28 days after
right lung resection and monocrotaline injection for trans-
plantation into normotensive recipients. After anesthesia,
the rats were intubated through a tracheostomy and venti-
lated as described above with an inspired oxygen fraction
of 1. A median laparosternotomy was performed, and 300
units of heparin (Hepalean; Organon Teknika, Toronto,
Canada) was injected into the inferior vena cava. For the
retrieval of the heart-lung block, the inferior vena cava and
the left atrial appendage were incised and a 14-gauge intra-
venous catheter was placed into the main PA through a
right ventriculotomy. The lungs were then flushed through
this catheter with 20 mL of a low-potassium dextran–5%
glucose preservation solution (Perferdex; Biophausia,
Uppsala, Sweden) containing 500 µg/L of alprostadil (for-
merly, prostaglandin E1; ProstinVR; Upjohn, Don Mills,
Ontario, Canada) from a height of 30 cm. This solution is
used in the clinical lung transplant program at the
University of Toronto. Immediately after the lungs were
flushed, the tracheostomy tube was clamped after inspira-
tion to preserve the lungs in the inflated state. The heart-
lung block was then removed and kept on ice at 4°C until
transplantation. In preparation for transplantation, 14-
gauge Teflon cuffs were placed around the left PA, left pul-
monary vein (PV), and the left main bronchus according to
techniques previously described.15,16
Recipient animals were anesthetized, endotracheally
intubated, and ventilated. A left thoracotomy was per-
formed through the fifth intercostal space. The left lung
was mobilized by transecting the pulmonary ligament. The
left PA, PV, and bronchus were identified and clamped with
microsurgical aneurysm clamps. The cuffs on the donor
lung PA, PV, and bronchus were inserted through incisions
in the corresponding recipient structures, and the anasto-
moses were fixed with 7-0 polypropylene ties. The warm
ischemic time was standardized at 20 minutes; this is the
period of time between removal of the lung from the ice
bath and restoration of blood flow. Heparin (100 units) was
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Fig 1. PA pressure and RV hypertrophy. A, Mean PA pressures in rats 28 days after right lung resection and
monocrotaline injection were more than 3-fold higher than in normal control rats. However, mean PA pressures 14
and 28 days after transplantation of the left lungs from pulmonary hypertensive rats into normotensive recipients
were only mildly elevated from control values, confirming effective pressure unloading. Bars represent mean ±
SEM for controls (n = 4), lung resection and monocrotaline injection (n = 7), lung transplantation at 14 days (n =
3), and lung transplantation at 28 days (n = 7). B, RV hypertrophy detected as a more than 2-fold increase in the
RV/LV+S mass ratio was evident 28 days after right lung resection and monocrotaline injection relative to normal
controls. However, RV hypertrophy did not occur 14 or 28 days after transplantation of hypertensive left lungs into
normal rats and is consistent with the absence of pulmonary hypertension in these animals. Bars represent mean ±
SEM for controls (n = 4), lung resection and monocrotaline injection (n = 10), lung transplantation at 14 days (n =
5), and lung transplantation at 28 days (n = 7). 
A B
injected into the intrathoracic inferior vena cava, the trans-
planted lung was inflated by removing the clamp on the
bronchus, and the lung was reperfused by unclamping the
PV followed by the PA. A chest tube was left in the pleur-
al space and the thoracotomy incision was closed in layers
with absorbable sutures. Inflation of the transplanted lung
was confirmed by a postoperative chest radiograph.
Immunosuppressive agents were not used. 
PA pressure measurement. PA pressures were measured
in normal control rats, in rats 28 days after right lung resec-
tion and monocrotaline injection, and 14 and 28 days after
transplantation of the hypertensive left lungs into normoten-
sive recipient rats. Anesthesia was induced in an induction
chamber with isoflurane (Zeneca, Mississauga, Ontario,
Canada) and maintained with the animals breathing sponta-
neously through a face mask. The PA was cannulated with a
silicone rubber tube (0.64-mm outer diameter) through the
right external jugular vein by means of a previously described
closed chest technique.17,18 Pressures were recorded by a
transducer (MS20; Electromedics, Englewood, Colo), ampli-
fier (Interface 4600; Gould, Inc, Cleveland, Ohio), and mon-
itor (V1000, Gould).
Tissue preparation and assessment of RV hypertrophy.
After the hemodynamic measurements were completed, a
midline sternotomy was performed to expose the heart and
lungs. Heparin (500 units) was injected into the RV cavity.
The main PA was cannulated with polyethylene tubing (2.08-
mm outer diameter) through a right ventriculotomy, the lungs
were perfused with phosphate-buffered saline solution (NaCl
8 g, KCl 0.2 g, Na2HPO4 1.4 g, KH2PO4 0.96 g/L) at 20 cm
H2O to clear the blood, and the heart and lungs were removed
en bloc. The PA was perfused with a warm (60°C) barium-
gelatin mixture at 100 cm H2O for 5 minutes to evenly dis-
tend all precapillary vessels and allow reproducible structur-
al assessment. The lungs were then distended and fixed by
perfusion with 10% formalin through the trachea for 48
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Fig 2. Percent wall thickness of muscular arteries. A to D, Representative photomicrographs of left lung sections
stained with Movat pentachrome demonstrate thickening of the wall (arrows) of muscular PAs 28 days after right
lung resection and monocrotaline injection (B) relative to normal controls (A). There was a progressive reduction
in wall thickness 14 (C) and 28 (D) days after transplantation of the hypertensive lungs into normotensive recipi-
ents. Scale bar =100 µm. 
hours, paraffin embedded, and sectioned for light
microscopy. The right ventricle (RV) was dissected from the
left ventricle and septum (LV+S), both were weighed sepa-
rately, and the RV/LV+S weight ratio was calculated. 
Morphometric analysis of PA structure. Sections stained
with Movat pentachrome were analyzed by observers blinded
to the treatment group. All barium-filled arteries were
assessed at 400× magnification. The external diameter and
wall thickness were measured for muscular arteries of size
ranges 50-100 µm and 101-150 µm. Percent wall thickness
(%WT), an index of medial hypertrophy, was calculated
according to the following formula: %WT = (2 × WT)/exter-
nal diameter × 100. Extension of muscle into the normally
nonmuscular PAs between 15 and 50 µm in diameter was
evaluated by the percentage of arteries with a complete or par-
tial medial muscle layer. The arterial density was determined
from each section by counting all arteries and alveoli in each
of 10 random fields at 200× magnification. Arterial density
was expressed as the number of arteries per 100 alveoli.
Evaluation of cellular proliferation. Cellular prolifera-
tion was evaluated by immunohistochemical staining with a
monoclonal antibody against the proliferating cell nuclear
antigen (PCNA). To detect PCNA, we incubated deparaf-
finized tissue sections for 60 minutes at room temperature
with nuclease (Cell proliferation kit; Amersham Inter-
national, Buckinghamshire, United Kingdom). Sections were
incubated overnight at 4°C with a monoclonal antibody
against PCNA (PC10, dilution 1:100 in phosphate-buffered
saline solution; DAKO Corporation, Carpinteria, Calif), then
with a peroxidase-conjugated secondary antibody (15
µL/mL; Amersham International), developed with 3,3´-
diaminobenzidine (Sigma Chemical Company, St Louis, Mo)
and counterstained with eosin. Additional sections were incu-
bated with nonimmune mouse immunoglobulin G as a nega-
tive control and showed no background staining. 
PCNA-positive cells were quantified in a blinded fashion
by counting the number of positively stained nuclei in 10
randomly selected arteries between 15 and 100 µm in diame-
ter. The total number of nuclei was determined in the same
arteries from the corresponding hematoxylin and eosin–
stained serial sections, and the percentage of PCNA-positive
cells relative to total cell number was calculated. 
Data analysis. Data are expressed as mean ± SEM.
Statistical significance was assessed by means of a 1-way
analysis of variance with post hoc testing by the Fisher pro-
tected least significant difference method except for body-
weight change, which was assessed by means of a paired t test. 
Results
Perioperative survival. Normal rats (n = 4) served
as one control group and did not undergo any treat-
ment. Of the 37 rats undergoing pulmonary resection
and monocrotaline injection, 7 did not survive the pro-
cedure. By postoperative day 28, the 30 surviving rats
exhibited signs of respiratory distress and were failing
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Fig 2. E and F, PA wall thickness, expressed as a percentage of external diameter as described in the “Methods”
section, was increased 4-fold in 50-100–µm vessels (E) and 101-150–µm vessels (F) 28 days after right lung resec-
tion and monocrotaline injection relative to normal controls. There was progressive normalization of wall thickness
14 and 28 days after transplantation of the hypertensive left lungs into normotensive recipient rats. Bars represent
mean ± SEM for control (n = 4), lung resection and monocrotaline injection (n = 10), lung transplantation at 14
days (n = 5), and lung transplantation at 28 days (n = 7).
E F
to thrive as indicated by a 5% reduction from their pre-
operative weight (345 ± 9 vs 363 ± 8 g, P = .005, n =
30). One third (n = 10) were randomly selected as a
baseline hypertensive group and the remaining rats (n =
20) underwent transplantation of the hypertensive left
lung into normotensive recipients. The ischemic period
between the time the lung was harvested and blood
flow was restored was 98 ± 5 minutes. Six recipient rats
did not survive the transplant procedure. The surviving
recipient rats were killed at 14 (n = 5) and 28 days (n =
7) after transplantation.
PA pressure and RV hypertrophy. Mean PA pres-
sures were elevated more than 3-fold in rats 28 days after
right lung resection and monocrotaline injection relative
to normal controls (Fig 1, A). Pulmonary hypertension
was associated with marked RV hypertrophy, indicated
by a more than 2-fold increase in the RV/LV+S weight
ratio (Fig 2, B). The hypertensive left lungs explanted
from rats 28 days after right lung resection and
monocrotaline injection were transplanted into nor-
motensive recipients. We then confirmed hemodynamic
unloading of the transplanted lung by the observation
that mean PA pressures were not significantly different
from control values 14 days after transplantation and
were only mildly elevated by day 28 (Fig 1, A, P = .02
for transplant [28 days] vs control). Hemodynamic
unloading was further supported by the observation that
RV hypertrophy did not develop in the recipient rats 14
or 28 days after transplantation (Fig 1, B).
Pulmonary vascular remodeling. We next evaluat-
ed PA structure in the hypertensive lungs from rats 28
days after right lung resection and monocrotaline injec-
tion. There was a 4-fold increase in percent wall thick-
ness, an index of medial hypertrophy, in the hyperten-
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Fig 3. Muscularization of peripheral PAs and arterial density. A to D, Representative photomicrographs of left lung
sections stained with Movat pentachrome demonstrate extension of smooth muscle (arrows) into small peripheral
PAs 28 days after right lung resection and monocrotaline injection (B) relative to the normally nonmuscular arter-
ies seen in normal control rats (A). There was a progressive decrease in arterial muscularization 14 (C) and 28 (D)
days after transplantation of hypertensive left lungs into normotensive recipients. Scale bar = 100 µm. 
sive lungs relative to normal controls for both the 50-
100–µm and 101-150–µm vessel size ranges (Fig 2, A
and B, and Fig 2, E and F). However, there was pro-
gressive normalization of wall thickness 14 and 28
days after unloading of the hypertensive left lungs by
transplantation into normotensive recipients (Fig 2, C
and D, and Fig 2, E and F). 
Small peripheral PAs (15-50 µm in diameter) in nor-
mal lungs are nonmuscular in that they lack a smooth
muscle layer, as shown in Fig 3, A. However, with the
development of obstructive pulmonary vascular dis-
ease, the peripheral PAs become muscularized, as seen
in the lungs from rats 28 days after right lung resection
and monocrotaline injection (Fig 3, B). We quantified
the number of small PAs that were partially or com-
pletely muscularized and found a more than 4-fold
increase in the hypertensive lungs relative to normal
controls (Fig 3, E). However, when the hypertensive
lungs were unloaded by transplantation into normoten-
sive recipients, regression of the abnormal PA muscu-
larization was apparent 14 and 28 days later (Fig 3, C
and D, and Fig 3, E). 
Because obstructive pulmonary vascular disease is
also characterized by loss of peripheral PAs, we next
evaluated arterial density by quantifying the number of
arteries per 100 alveoli in the lung sections. There was
a 58% reduction in arterial density in lungs from rats 28
days after right lung resection and monocrotaline injec-
tion relative to normal controls (Fig 3, F). Whereas
hemodynamic unloading induced marked reductions in
medial hypertrophy and peripheral muscularization,
arterial density was only modestly improved either 14
or 28 days after transplantation (Fig 3, F). 
We next examined the right lung of recipient rats to
evaluate the impact of transplanting the hypertensive
left lung on the structure of the remaining pulmonary
vasculature. Arterial density remained normal (3.5 ±
0.4 and 3.3 ± 0.2 arteries per 100 alveoli at 14 and 28
days) relative to untreated controls (3.3 ± 0.3). Medial
thickness was also normal (5.5% ± 0.2% and 6.8% ±
0.6% wall thickness at 14 and 28 days) relative to
untreated controls (7.2% ± 1.5%), as was musculariza-
tion of peripheral arteries (17.5% ± 2.3% [14 days] and
20.0% ± 2.9% [28 days] vs 19.4 ± 1.2% [control]).
Cellular proliferation. One mechanism contributing
to medial hypertrophy and peripheral muscularization
in obstructive pulmonary vascular disease is prolifera-
tion of smooth muscle cells in the PA wall. We there-
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Fig 3. E, There was a more than 4-fold increase in the percentage of partially or completely muscularized arteries
15-50 µm in diameter 28 days after right lung resection and monocrotaline injection relative to normal controls. A
progressive reduction in arterial muscularization was evident 14 and 28 days after transplantation of the hyperten-
sive left lungs into normotensive recipients. F, Pulmonary arterial density (arteries/100 alveoli) was reduced by
58% 28 days after right lung resection and monocrotaline injection. Arterial density remained low 14 and 28 days
after transplantation of the hypertensive left lungs into normotensive recipients. Bars represent mean ± SEM for
control (n = 4), lung resection and monocrotaline injection (n = 10), transplantation at 14 days (n = 5), and trans-
plantation at 28 days (n = 7).
E F
fore looked for evidence of PA cellular proliferation by
immunoreactivity for the PCNA. Indices of PCNA-pos-
itive cells are low in normal PAs (Fig 4, A, and Fig 4E)
in contrast to a more than 9-fold increase 28 days after
right lung resection and monocrotaline injection (Fig 4,
B, and Fig 4E). When the hypertensive lungs were
unloaded by transplantation into normotensive recipi-
ents, the number of PCNA-positive cells returned
toward baseline levels by days 14 and 28 (Fig 4, C and
D, and Fig 4E). We also examined the lungs for evi-
dence of cellular apoptosis using the in situ TUNEL
(terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling) assay; however, none was
detected in PAs either 14 or 28 days after transplanta-
tion (data not shown).
Discussion
Patients with congenital heart defects and with a
fixed increase in pulmonary vascular resistance as a
result of obstructive pulmonary vascular disease repre-
sent a therapeutic challenge. These patients may not be
candidates for surgical correction of their congenital
heart lesion because of the risk of postoperative pul-
monary hypertension and RV failure. However, if the
structural changes in the pulmonary circulation associ-
ated with obstructive pulmonary vascular disease could
be reversed, surgical correction of the heart defect
might be accomplished with acceptable risk. 
Our laboratory has studied the pathobiology of the
development and regression of pulmonary vascular dis-
ease. We have found that PAs from rats with experi-
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Fig 4. Cellular proliferation. A to D, Representative photomicrographs of immunoperoxidase staining of left lung
sections with a monoclonal antibody against PCNA demonstrate positive nuclei (arrows) suggesting increased cel-
lular proliferation in the PA wall 28 days after right lung resection and monocrotaline injection (B) relative to nor-
mal controls (A). Positive nuclei were markedly reduced 14 (C) and 28 (D) days after transplantation of the hyper-
tensive left lungs into normotensive recipients. Scale bar = 50 µm. 
mental pulmonary vascular disease hypertrophy as a
result of smooth muscle cell proliferation when grown
under tension in an organ culture model.10 Further-
more, when the tension is “unloaded,” smooth muscle
cell proliferation stops and apoptosis is induced, lead-
ing to regression of PA hypertrophy. We therefore
hypothesized that a similar mechanism may be active
in vivo and could potentially be exploited to reverse
pulmonary vascular disease in patients with congenital
heart defects. To test this hypothesis, we developed a
model in which hypertensive rat lungs with experimen-
tal pulmonary vascular disease were hemodynamically
unloaded by transplantation into syngeneic, normoten-
sive recipient rats. 
In these experiments we show that advanced obstruc-
tive pulmonary vascular disease develops in rats 28
days after right lung resection and monocrotaline injec-
tion. Furthermore, unloading the pulmonary circulation
of the hypertensive lungs by transplantation into nor-
motensive recipient rats results in improvement in
medial hypertrophy and peripheral muscularization
associated with a reduction in PA cellular proliferation
rates. However PA density, although somewhat
improved, remains markedly below baseline levels.
In this model, unloading of the hypertensive lungs is
accomplished by transplantation into normotensive
recipients. To maximize the potential for unloading, we
transplanted hypertensive lungs into healthy recipients
rather than the usual clinical situation of transplanting
a normal lung into a hypertensive recipient. We have
documented that PA pressures are normal 14 days after
transplantation and only mildly elevated by day 28.
This observed increase in PA pressure after transplan-
tation is not due to the development of vascular disease
in the native pulmonary circulation, because arterial
density, muscularization, and medial thickness all
remained normal. However, it may be due to an
improvement in cardiac output as the animals recover
from the early postoperative period or to the develop-
ment of some degree of stenosis at the PA anastomoses,
even though all were patent at the time of tissue harvest
and barium injection. 
Consistent with an absence of major pulmonary hyper-
tension, RV hypertrophy did not develop in the recipient
animals. We presume that pulmonary blood flow to the
transplanted lung is also reduced as a result of shunting
toward the normal lung, although this was not measured
directly. We have shown improvement in the structure of
diseased PAs after unloading. However, we have not
measured pulmonary vascular resistance, which must be
reduced to have a favorable impact on the risk of correc-
tive surgery in patients with congenital heart defects.
Arterial density was reduced with the development of
obstructive pulmonary vascular disease in this model.
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Fig 4E. The percentage of nuclei stained positive with an anti-PCNA antibody was elevated more than 9-fold in the
PA wall of rats 28 days after right lung resection and monocrotaline injection relative to normal controls. The per-
centage of PCNA-positive cells in the PAs of hypertensive lungs returned to control values 14 and 28 days after trans-
plantation into normotensive recipients. Bars represent mean ± SEM from control (n = 4), lung resection and
monocrotaline injection (n = 10), lung transplantation at 14 days (n = 5), and lung transplantation at 28 days (n = 7).
E
We observed a modest improvement in arterial density
28 days after unloading of the hypertensive lungs; how-
ever, it was still markedly depressed relative to that of
normal controls. Reduced arterial density contributes to
the fixed increase in pulmonary vascular resistance in
patients with obstructive pulmonary vascular disease.6-9
Although arterial density could continue to improve
beyond 28 days, the results with unloading of the pul-
monary circulation may be limited by a persistent
decrease in arterial density. Therefore, concomitant
angiogenic therapy19 could theoretically be useful in
addition to hemodynamic unloading as a method of
restoring the PA structure.
Regression of PA medial hypertrophy in organ cul-
ture is associated with the induction of apoptosis,
which was detected up to 1 week after stress unload-
ing.10,20 However, we did not observe high levels of
apoptosis in PAs after unloading in this in vivo model
(data not shown). Apoptosis may therefore be an early
event that occurs before day 14, which is the earliest
time point that we have examined. Further reductions
in medial hypertrophy and peripheral muscularization
may be due to low levels of ongoing apoptosis or
resorption of extracellular matrix components.20
PA banding has been proposed as one method of
unloading the pulmonary circulation to induce
regression of pulmonary vascular disease.11 However,
unloading of the pulmonary circulation by banding of
the main PA is limited by the degree of cyanosis that
results from increased right-to-left shunting across
cardiac septal defects. Therefore, alternative strate-
gies will likely be required to make this approach
clinically applicable. For example, unilateral PA
banding might allow for regression of pulmonary
vascular disease in the banded lung while maintain-
ing adequate flow to the contralateral lung. Improved
PA structure in the banded lung alone may be suffi-
cient to permit subsequent surgical repair of the heart
defect with a reasonable safety margin while avoid-
ing the consequences of banding the main PA.
Furthermore, extracorporeal membrane oxygenation
has been used to successfully reduce perioperative
PA pressures21 and could in theory promote recovery
of pulmonary vascular structure.
Patients with pulmonary vascular disease as a result
of a cardiac defect can be treated by single lung trans-
plantation with cardiac repair. This study supports the
intriguing concept that a single lung transplant with
cardiac repair will not only provide immediate life-sav-
ing therapy but could also unload the remaining native
lung, possibly leading to reversal of the pulmonary vas-
cular changes. This clinical scenario may be the only
situation in which the concept of hemodynamic
unloading to reverse what is conventionally thought of
as irreversible pulmonary vascular disease can be safe-
ly studied in human beings. 
Because of our understanding of the cellular mecha-
nisms involved, we have been able to develop thera-
peutic strategies that target the critical biologic
processes directly, in addition to reversing pulmonary
vascular disease by hemodynamic unloading. For
example, we have identified that cellular proliferation
in experimental pulmonary vascular disease is mediat-
ed by the activity of proteolytic enzymes including ser-
ine elastases and matrix metallo-proteinases. These
enzymes release growth factors and up-regulate αvβ3
ligands such as tenascin C, which in turn promote the
proliferative response by activating growth factor
receptors.23 The results of targeting these enzymes with
specific inhibitors are that smooth muscle cell prolifer-
ation is arrested, apoptosis is induced, extracellular
matrix is resorbed, and the pulmonary vascular changes
regress in both organ culture21 and whole animal mod-
els.14 Therefore, other strategies may be useful in con-
junction with or as an alternative to hemodynamic
unloading to reverse pulmonary vascular disease.
Applicability of these observations to human pul-
monary vascular disease is limited by the suitability of
the model. Lung resection to increase blood flow in the
remaining PA modifies the response to monocrotaline so
that gene expression and remodeling closely resemble the
human disease.12,13 However, significant differences in
the time course and pathologic findings still exist. A sec-
ond limitation relates to the use of transplantation as a
method to unload the pulmonary circulation in which
we could not control for the potential impact of dener-
vation and disruption of bronchial blood supply.
In summary, strategies to unload the pulmonary cir-
culation or to activate the critical mechanisms by
means of a biologic approach may improve the struc-
tural changes associated with obstructive pulmonary
vascular disease in patients with congenital heart
defects. Angiogenic therapies may afford additional
benefit by improving arterial density, which appears
less responsive to unloading than does medial hyper-
trophy or muscularization of peripheral PAs.
Therefore, a multifaceted approach to this challeng-
ing problem seems promising and should be critical-
ly evaluated in an attempt to improve the outcome for
these patients.
We thank Dr Michael Borger, who reviewed the statistical
analysis, and J. Jowlabar, J. Matthews, and J. Edwards for
secretarial assistance. 
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Discussion
Dr Fred A. Crawford (Charleston, SC). Dr O’Blenes, pul-
monary hypertension has been documented to occur and
progress after the successful repair of anomalies such as ven-
tricular septal defects and complete atrioventricular septal
defects. Presumably these lungs have been unloaded by such
a repair. How do you explain that in light of your findings? 
Dr O’Blenes. In the experiment we presented, the PA pres-
sures were unloaded to normal pressure ranges. If you were
to repair a ventricular septal defect in a patient with fixed pul-
monary hypertension, for example, you would expect PA
pressures to remain high in the postoperative period. That
could explain why pulmonary hypertension might progress in
that group of patients: the shunt is being closed but the pres-
sure to that vasculature is not being restricted. 
Another possibility is that some patients may be predis-
posed to the development of severe pulmonary hypertension,
not purely on the basis of increased flow. They may have a
predisposition to a sort of primary pulmonary hypertension
that will progress despite the repair. 
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